LIFECARE ASA: Extraordinary General Meeting

Lifecare ASA, a MedTech company developing next-generation continuous glucose monitoring (CGM) technology, will hold an Extraordinary General Meeting on 2 January 2026 at 16:00 (CET).

Reference is made to earlier communication regarding the partially underwritten rights issue of new shares with preferential rights for existing shareholders, targeting total gross proceeds between NOK 80 million and NOK 100 million (the "Rights Issue").

An Extraordinary General Meeting will be held on 2 January 2026 to resolve the following matters related to the Rights Issue:

* Share capital increase * Issuance of Warrants Series 1 and Series 2 * Board authorization to issue shares as underwriting fee * Issuance of Additional Warrants Series 1 and Series 2

The meeting will be conducted as a combined physical and digital meeting. Shareholders who wish to participate and vote at the Extraordinary General Meeting must be registered with a user profile in the meeting portal Orgbrain (www.orgbrain.no (http://www.orgbrain.no/)). Attendance will be possible either in person or digitally through Orgbrain.

The notice with the complete agenda and supporting documents is available at https://lifecare.no/events/ (https://lifecare.no/investor/financial-calendar/).

About us Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-12-11 15:00 CET.